Ultimate magazine theme for WordPress.

AstraZeneca vaccine use to be temporarily deferred in Ireland over reports of ‘serious blood clotting’ reports

AstraZeneca vaccine uses to be temporarily deferred in Ireland over reports of ‘serious blood clotting’ reports.

#AstraZeneca #vaccine #temporarily #deferred #Ireland #reports #blood #clotting #reports #limericknewswire

THE use of the AstraZeneca vaccine for Covid-19 is to be “temporarily deferred” in Ireland – due to new reports of “serious blood clotting.”

Deputy Chief Medical Officer Dr. Ronan Glynn has announced that following discussions by the HPRA and NIAC yesterday, the administration of the AstraZeneca jab in Ireland would be brought to a halt.

AstraZeneca vaccine use to be temporarily deferred in Ireland over reports of ‘serious blood clotting’ reports
Deputy Chief Medical Officer Dr. Ronan Glynn
PA: Press Association

This is due to four new reports of “serious” blood clotting in adults following the jab’s administration from the Norwegian Medicines Agency.

Dr. Glynn said that it had not been concluded that there is any link between the AstraZeneca vaccine in these cases.

However, the Deputy CMO said that NIAC made the recommendation a “precautionary principle.”

NIAC is due to meet again this morning, and Dr. Glynn has said a further statement will be released after the meeting.

Dr. Glynn said: “Following new information received from the Norwegian Medicines Agency on Saturday evening 13th March and following discussions with the Health Products Regulatory Authority (HPRA), the National Immunisation Advisory Committee (NIAC) has recommended that the administration of Covid-19 Vaccine AstraZeneca be temporarily deferred from this morning, Sunday 14th March.

‘PRECAUTIONARY’ MEASURE

“This recommendation has been made following a report from the Norwegian Medicines Agency of four new reports of serious blood clotting events in adults after vaccination with Covid-19 Vaccine AstraZeneca.

“It has not been concluded that there is any link between the COVID-19 Vaccine AstraZeneca and these cases.

“However, acting on the precautionary principle and pending receipt of further information, the NIAC has recommended the temporary deferral of the COVID-19 Vaccine AstraZeneca vaccination program in Ireland.

“The NIAC is due to meet again this morning. A further statement will follow thereafter.”

NORWAY INCIDENTS

Yesterday, Norwegian health officials reported that three more cases of blood clots or brain hemorrhages took place in young people.

While those young people had received the AstraZeneca jab, the Norwegian Medicines Agency can not yet say whether they are vaccine-related.

The World Health Organisation has said no causal link had been established between the vaccine and blood clotting.

Denmark, Norway, and Iceland also temporarily paused using the AstraZeneca jab over concerns about post-vaccine blood clots on Thursday.

ASTRAZENECA STATEMENT

AstraZeneca has said that an analysis of their safety data of 17million doses of the jab shows “no evidence” of increased risk of blood clots due to the jab.

The jab manufacturer said that the number of pulmonary embolisms, deep vein thrombosis, and thrombocytopenia are “not greater” than the number in the general unvaccinated population.

An AstraZeneca spokesman said: “An analysis of our safety data that covers reported cases from more than 17 million doses of vaccine administered has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia with Covid-19 Vaccine AstraZeneca.

“In fact, the reported numbers of these types of events for Covid-19 Vaccine AstraZeneca are not greater than the number that would have occurred naturally in the unvaccinated population.

“In clinical trials, no trends or patterns were observed concerning pulmonary embolism, deep vein thrombosis, or events possibly related to thrombocytopenia.

“A careful review of all available safety data including these events is ongoing, and AstraZeneca is committed to sharing information without delay.

“We also note that the European Medicine Agency (EMA) has asked for an assessment of events related to thrombocytopenia from other Covid-19 vaccine manufacturers (per communication 11 March).